Adherium

What Adherium does

Adherium Limited (ASX: ADR) is an Australian digital health company founded in 2001 and listed on the ASX in 2015, focused on remote monitoring of inhaled medication adherence for asthma and COPD patients. The company's core product is the Hailie Smartinhaler platform—FDA-cleared Bluetooth-enabled sensors that attach to inhaler devices (pMDIs, Diskus, Respimat, HandiHaler, Turbuhaler, Ellipta), paired with a regulatory-compliant cloud data platform, a patient mobile app, and a clinical/customer portal. Adherium holds an extensive patent portfolio covering sensor designs across major inhaler types and FDA clearances for use with inhalers from AstraZeneca (Airsupra, Breztri, Symbicort/Vannair), GSK (Ellipta), and Teva (ProAir); the company has shipped over 180,000 devices across 30 countries and claims the most clinically supported respiratory adherence solution on the market (>85 studies, 13,000+ patients, >100 peer-reviewed publications).

The business model centres on three revenue streams: recurring Remote Patient Monitoring (RPM) subscriptions in the US under favorable CPT reimbursement codes (~$1,400/patient/year to physicians), clinical trial sensor contracts with pharmaceutical companies and CROs, and one-time device sales. In H1 FY2026, revenue decomposed to A$278,783 from RPM subscriptions (up 103% QoQ), A$192,000 from clinical trial contracts, and A$76,075 from device sales, totalling A$801,402 and reflecting 60% YoY growth. Adherium sells primarily through direct enterprise sales to US health systems, payers, and specialty respiratory networks, supplemented by channel partnerships with Monaghan Medical Corporation for US distribution and integrated deployments with Allergy Partners (110+ clinic locations), HGE Health, SENTA Partners, and Intermountain Health (iCARE program). Management targets 10,000 RPM device shipments by end of FY2026 against a verified pipeline of 40,000 eligible patients.

The company employs 51-100 staff across Melbourne (corporate HQ at Level 5, 447 Collins Street; R&D with Planet Innovation), Auckland (regional HQ), and operates through wholly-owned subsidiaries in the US (Adherium North America, Inc.), the UK (Adherium Europe Ltd), and New Zealand (Adherium (NZ) Limited). Leadership was substantially refreshed in 2025-2026 to support US scaling: Dawn Bitz was appointed CEO in July 2025, John Perry joined as Chief Commercial Officer in June 2026, and the board was reconstituted with Trudell Medical's George Baran as Non-Executive Chair and BioScience Managers' Victoria Durrans as Director. The company has been funded through repeated post-IPO equity raises (notably A$8.37M in April 2024 and A$6.7M institutional plus up to A$0.82M retail in February 2026) and has secured alliances with life-sciences VC BioScience Managers as a major shareholder.

Name

Adherium

Legal name

Adherium Limited

Website

https://adherium.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Adherium (ASX: ADR) is an Australian digital health company that sells the FDA-cleared Hailie Smartinhaler platform—Bluetooth inhaler sensors plus a cloud data and RPM platform—for remote monitoring of medication adherence in asthma and COPD patients, serving US health systems, payers, specialty respiratory networks, and pharmaceutical clinical trials.

Ownership category

akta.pro rank

Product category

Remote Patient Monitoring

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

akta.pro primary industry

Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH)

Keywords

• Remote patient monitoring
• Smart inhaler technology
• Respiratory adherence platform
• Digital health subscriptions
• Medication adherence monitoring

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure, Supply Chain

Revenue model

1. Remote Patient Monitoring (RPM) Subscriptions: Recurring Remote Patient Monitoring subscription revenue from US healthcare market. Management reports A$278,783 in RPM subscriptions for first-half FY26, with quarterly growth of 103% quarter-on-quarter. CPT codes enable physician billing of approximately $1,400 per patient annually.
2. Clinical Trial Contracts: Revenue from clinical trial sensor and software supply contracts. First-half FY26 revenue of A$192,000 from clinical trial contracts.
3. Device Sales: One-time device sales of Hailie Smartinhaler sensors. First-half FY26 revenue of A$76,075 from device-only sales. 4,666 devices delivered in CY2025 including 2,034 RPM devices.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Adherium sells the Hailie® Smartinhaler® platform, consisting of FDA-cleared Bluetooth-enabled sensors that attach to patients' inhaled medication devices, a companion mobile application, and a cloud-based data management infrastructure. The integrated Hailie RPM Platform enables physicians and payers to remotely monitor medication adherence, generate CPT-code compliant reimbursement reports, and manage difficult-to-treat asthma and COPD patients across US health systems, specialty networks, and pharmaceutical clinical trials.

Product overview

Adherium's Hailie® Smartinhaler® is a unified digital respiratory medication adherence platform consisting of FDA-cleared Bluetooth-enabled sensors that attach to patients' existing inhalers, a companion mobile app providing real-time medication use feedback, a regulatory-compliant cloud data management infrastructure, and clinical/customer portals for reimbursement reporting. The Hailie® RPM Platform integrates these components to enable Remote Patient Monitoring reimbursement for physicians treating asthma and COPD patients, while the Smartinhaler® sensors form the core hardware component with coverage across multiple inhaler types including pMDIs and dry powder inhalers from pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

• Hailie Smartinhaler: FDA-cleared Bluetooth-enabled sensors that attach to inhalers and track medication use, providing real-time feedback via the Hailie app.
• Hailie RPM Platform
• Smartinhaler

Products and services

• Hailie Smartinhaler Sensors FDA-cleared Bluetooth-enabled sensors that attach to inhaled medication devices (pMDIs, Diskus, Ellipta, Turbuhaler, HandiHaler, Respimat) and capture medication use and physiological data for asthma and COPD patients. Sold to US health systems, payers, providers, specialty respiratory networks, and pharmaceutical companies.
• Hailie App Mobile companion application that monitors medication activation, adherence and timing, providing real-time feedback to patients on their medication use patterns. Available on iOS and Android.
• Hailie Data Management Platform Regulatory-compliant cloud infrastructure for secure storage and management of patient medication use data, with proprietary algorithms generating auditable reimbursement reports for payers and providers. Supports future data and freemium service capabilities.
• Hailie Portal Clinical portal providing reimbursement-compliant reports, billing support, and audit trail for healthcare providers and payers. Powers CPT-coded RPM billing workflows for asthma and COPD patient management.
• Hailie RPM Platform Comprehensive Remote Patient Monitoring (RPM) platform integrating Hailie sensors, mobile app, cloud data management and clinical portal to enable physician reimbursement through US CPT codes (approximately $1,400 per patient annually) for respiratory medication adherence monitoring. Sold under recurring subscription to US health systems, payers, and specialty respiratory networks.

Quantifiable outcome

• 180% increase in adherence to preventative medication in children, 59% in adults
• +7 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• VRIminorStrategic or Co-development Partner · 18 June 2024Strategic partnership for respiratory care solutions.
• NuvoAir MedicalminorStrategic or Co-development Partner · 10 January 2024Partnership to enhance patient outcomes through respiratory monitoring integration.
• Allergy PartnerscoreStrategic or Co-development Partner · 25 September 2023Major asthma partnership for RPM program rollout. Allergy Partners is one of the largest allergy and asthma networks in US with 110+ clinic locations serving 90,000+ asthma patients. Adherium manages end-to-end activation of patients onto fee-for-service RPM workflow.
• AvillionminorStrategic or Co-development Partner · 2 June 2022Collaboration to support Avillion-sponsored clinical study using Hailie Smartinhaler technology.
• Planet InnovationcoreStrategic or Co-development Partner · 21 April 2020Strategic device hardware and software development partnership to enhance Adherium's leading device coverage position in both asthma and COPD. Planet Innovation supports development of next-generation sensors with enhanced physiological measurement capabilities. Planet Innovation has proven track record in highly regulated medical device hardware and software development.
• HGE HealthcoreStrategic or Co-development Partner · 16 April 2020US disease management collaboration for COPD with HGE Health's telemedicine platform integration. HGE Health's clinically-validated algorithms assess medication adherence allowing effectiveness evaluation on patient-by-patient basis. Collaboration focuses on COPD patients with plans to extend to asthma management.
• Monaghan Medical CorporationcoreChannel Partner/ Reseller/ DistributorMonaghan Medical Corporation partnership provides Adherium with access to targeted facilities across the US through strong customer relationships. Monaghan is dedicated to improving lives of people with respiratory conditions, and the partnership brings Hailie platform to complement their current product offering and expand into digital space.
• Intermountain HealthcoreStrategic or Co-development PartnerIntermountain Health iCARE respiratory program - one of the largest real-world respiratory monitoring programs. Combined Hailie Smartinhalers with connected monitoring devices, AI-driven behavioural engagement and clinical care oversight. Demonstrated 235% adherence improvement, 53% inpatient admission reduction.
• SENTA PartnerscoreStrategic or Co-development PartnerMajor asthma partnership with US-based SENTA partners for patient enrollment program in US market. Focus on uncontrolled, paediatric and adult asthma patients with high burden of disease and healthcare costs in secondary/tertiary care.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Emerging players

• Tenovi: RPM hardware and cellular gateway provider integrating with multiple chronic disease management platforms; Adherium technology integration partner. Comparable as an enabler of RPM programs that competes for the same health system/payer deployment slots.
• Rimidi: Respiratory clinical management platform integrated with EHR systems; Adherium technology partner. Comparable as a respiratory-focused RPM platform competing for similar health system and specialty practice customers.
• AMC Health: US RPM and virtual care provider offering chronic disease management including COPD; Adherium technology integration partner. Comparable as a broader RPM provider addressing similar payer and health system contracts.
• NuvoAir Medical: Digital respiratory care platform providing virtual pulmonary rehabilitation, RPM, and chronic condition management. Comparable as an emerging respiratory-focused RPM player addressing the same difficult-to-treat asthma/COPD populations with payer-facing value-based care models.

Direct peers

• Propeller Health: Direct competitor in connected inhaler sensors and respiratory RPM; acquired by ResMed in 2019. Most direct comparison for Adherium's Hailie Smartinhaler, targeting the same asthma/COPD adherence use case with similar Bluetooth sensor hardware.
• Aptar Pharma: Drug delivery device manufacturer (pMDIs, DPIs, nasal) supplying pharmaceutical companies globally. Comparable as a developer and manufacturer of inhaler-compatible digital health/drug delivery platforms serving the same asthma/COPD patient population.
• HGE Health: US COPD disease management company with telemedicine platform; active commercial partner of Adherium. Comparable as a respiratory RPM/disease management competitor covering overlapping COPD patient populations in the US payer/provider market.

Broad incumbents

• AstraZeneca: Major respiratory pharma manufacturer of Airsupra, Breztri, and Symbicort (all Adherium-cleared inhalers). Comparable as a pharma partner whose broader digital respiratory strategy and potential internal smart-inhaler development directly affects Adherium's addressable market.
• GSK: Major respiratory pharma manufacturer of Ellipta inhaler products (Hailie-cleared). Comparable as a pharma incumbent whose digital respiratory investments and inhaler portfolio strategy shape Adherium's market positioning.
• ResMed: Global leader in sleep apnea and respiratory care devices; parent of Propeller Health. Comparable as a broader respiratory medical device incumbent that now competes directly in connected inhaler RPM via Propeller and adjacent digital health capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Smartinhaler
• YouTubeyoutube.com/@adherium?si=Zhkz94U5EMyVH2cy
• LinkedInlinkedin.com/company/adherium
• Facebookfacebook.com/info

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries3 records

Funding overview

Funding rounds9 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adherium